23andMe

Founded in 2006, 23andMe operates as a pioneering biotechnology company focused on empowering individuals with access to and understanding of their genetic information. The organization is dedicated to advancing scientific discovery by facilitating large-scale genetic research, contributing to a deeper comprehension of DNA and human biology. Its core mission involves bringing individuals together to support research initiatives aimed at improving health outcomes and driving medical breakthroughs. The company's product portfolio encompasses genetic testing, consumer healthcare solutions, and genomic services, positioning it at the forefront of personalized medicine and preventative health.

With a workforce of 500 - 1,000 employees and operations spanning 2 locations, 23andMe has established a significant presence in the biotechnology sector. Its services include direct-to-consumer genetic testing kits, enabling users to explore their ancestry, health predispositions, and wellness traits. The company leverages advanced genotyping technologies and a robust data platform to deliver actionable insights. Key product areas include genetic testing, consumer healthcare, and biopharmaceutical research support, underscoring its multifaceted approach to leveraging genetic data for both individual benefit and broader scientific advancement.

Financially, 23andMe reported revenue of $118.3M. The company has a history of substantial funding rounds, attracting investment from prominent venture capital firms and strategic partners, supporting its ongoing research and development efforts. Its competitive landscape includes other major players in the genetic testing and personalized medicine space, such as Ancestry, Color, and Invitae. For deeper insights into its financial performance and operational scale, users can Explore financial highlights. To learn more about the people driving its innovation, oneView more...